查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生物製品市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按產品、應用、來源、製造和地理位置
市場調查報告書
商品編碼
1558417

生物製品市場規模和預測、全球和區域佔有率、趨勢和成長機會分析報告範圍：按產品、應用、來源、製造和地理位置

Biologics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing, and Geography
出版日期: | 出版商: The Insight Partners | 英文 200 Pages | 訂單完成後即時交付

價格

依據「2031 年生物製劑市場預測 - 全球分析 - 按產品、應用、來源、製造和地理位置」的新研究，該市場預計將從 2023 年的 4692 億美元成長到 2023 年的 4692 億美元。到2031 年將達到17,939 億；預計 2023-2031 年複合年成長率為 18.2%。市場成長歸因於慢性病病例的增加以及隨後多種疾病緩解療法的批准。發展中地區生物技術產業的發展可能為市場成長提供機會。然而，嚴格的法規和高昂的藥物開發成本阻礙了市場的成長。

生物製劑是製藥業最有前景的途徑之一，提供了治療各種疾病和醫療狀況的獨特方法。由於製藥和生技公司投入大量資金改善其生產設施，生物製品市場不斷成長。慢性病病例和診斷數量的增加需要複雜的診斷和治療藥物的供應，這推動了全球生物製品市場的發展。此外，不斷成長的需求、對創新療法的更高接受度以及不斷增加的臨床試驗預計將推動市場成長。然而，生物相似藥的批准是限制生物製劑市場擴張的主要方面之一。

2023年，北美佔據全球生物製品市場的主要佔有率。推動該地區市場成長的關鍵因素是慢性病的高盛行率、眾多領先的生物製藥公司、有利的報銷政策以及對研發的大量投資。根據 JAMA Network 發表的一篇文章，生物製劑占美國藥品總支出的 37%。生物製劑處方佔有率的不斷增加以及對開發標靶藥物的投資不斷增加正在促進市場成長。此外，反義、基因療法和 RNAi 療法等幾種新型生物藥物的批准預計將進一步推動市場成長。

發展中地區生技產業的發展為未來提供市場機會

在現代生物技術中，從基礎研究到創新醫學評估的許多過程都需要抗體。治療性抗體的開發為治療各種疾病開闢了新途徑，證明了這些顆粒的轉化能力。抗體在基於抗體的診斷中也至關重要，因為它們提供了準確可靠的疾病識別方法。政府不斷增加的支持、不斷增加的公私夥伴關係、不斷變化的疾病概況以及不斷增加的資助活動正在廣泛提高亞太地區、南美洲和中美洲以及中東和非洲等地區生物技術行業的績效。阿拉伯聯合大公國、沙烏地阿拉伯、阿曼、馬斯喀特、巴林、台灣、馬來西亞、印度、中國、新加坡和日本等國家是生物技術產業最有利的目的地之一。生物技術、遺傳學和細胞生物學領域的不斷進步有助於確定標靶治療的潛力。隨著生物技術產業擴大科學家的工具箱，基礎研究、轉化研究和臨床試驗的結合將繼續開發、研究和測試更多的化合物、技術和治療途徑。生物技術是中國的戰略產業。中國製造2025計劃旨在生產高科技產品，包括創新藥物。該計劃為中國製藥公司提出了刺激生物技術創新和增加出口的目標。此外，這些亞洲國家更注重利用基因組學、蛋白質組學和生物標記的進步進行診斷和治療應用。因此，發展中地區生物技術產業的持續發展預計將在未來幾年為生物製品市場創造機會。

基於產品的見解

根據產品，生物製品市場分為單株抗體、疫苗、重組荷爾蒙/蛋白質、細胞和基因治療等。單株抗體細分市場在 2023 年佔據最大的市場佔有率，並且可能在 2023 年至 2031 年期間實現最高的複合年成長率。

基於應用程式的見解

根據應用，市場分為癌症、傳染病、自體免疫疾病等。 2023 年，癌症細分市場佔據最大市場佔有率，預計 2023 年至 2031 年複合年成長率最高。

基於來源的見解

根據來源，市場分為哺乳動物和微生物。微生物細分市場將在 2023 年佔據更大的市場佔有率。哺乳動物表達系統主要用於開發基於病毒載體的重組蛋白和疫苗。最常用的哺乳動物細胞係是 CHO 和 HEK。 Perjeta（帕妥珠單抗）、Adcetris（brentuximab vedotin）、Kadycla（曲妥珠單抗emtansine）、Shingrix（帶狀皰疹疫苗）和Aimovig（erenumab）等產品都是在哺乳動物表達系統中生產的產品。

生物製劑市場：競爭格局與主要發展

艾伯維公司；輝瑞公司；三星生物製劑； ADMA 生物製劑公司；藥明生物；康泰倫特公司； AGC生物製劑； Crescendo 生物製劑有限公司； Zumutor 生物製品公司； Theriva 生物製劑；阿斯特捷利康；安進公司；艾維西亞生物製品公司；和 Quality Assistance sa 是生物製劑市場上的主要公司之一。

美國食品藥物管理局、疾病管制與預防中心 (CDC) 和全球疾病負擔研究是準備生物製劑市場報告時參考的主要和次要來源。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第 4 章：生物製品市場格局

  • 概述
  • PEST分析

第 5 章：生物製劑市場 - 主要市場動態

  • 生物製品市場 - 主要市場動態
  • 市場促進因素
    • 慢性病盛行率增加
    • 偏好外包製造業務
  • 市場限制
    • 生物製劑成本高
  • 市場機會
    • 發展中地區生物技術的演變
  • 未來趨勢
    • 公司的策略舉措
  • 促進因素和限制的影響：

第 6 章：生物製劑市場 - 全球市場分析

  • 生物製品市場收入，2021-2031
  • 生物製品市場預測分析

第 7 章：生物製劑市場分析 - 按產品

  • 單株抗體
  • 疫苗
  • 重組荷爾蒙/蛋白質
  • 細胞和基因治療
  • 其他

第 8 章：生物製劑市場分析 - 按應用

  • 癌症
  • 傳染病
  • 自體免疫疾病
  • 其他

第 9 章：生物製品市場分析 - 按來源

  • 哺乳動物
  • 微生物

第 10 章：生物製劑市場分析 - 按製造

  • 外包
  • 內部

第 11 章：生物製品市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 亞太地區其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 12 章：產業格局

  • 概述
  • 生物製品市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 13 章：公司簡介

  • AbbVie Inc
  • Pfizer Inc
  • Samsung Biologics Co Ltd
  • ADMA Biologics, Inc.
  • WuXi Biologics Inc
  • Catalent Inc
  • AGC Biologics AS
  • AstraZeneca Plc
  • Amgen Inc
  • Nitto Avecia
  • Quality Assistance s.a.

第 14 章：附錄

Product Code: TIPRE00002765

According to our new research study on "Biologics Market Forecast to 2031 - Global Analysis - by Product, Application, Source, Manufacturing, and Geography," the market is anticipated to grow from US$ 469.2 billion in 2023 and is projected to reach US$ 1,793.9 billion by 2031; it is expected to register a CAGR of 18.2% during 2023-2031. Market growth is attributed to increasing cases of chronic diseases and subsequent approvals for several disease-modifying therapies. Evolution of biotechnology industry in developing regions are likely to offer opportunities for the market growth. However, the stringent regulations and high drug development costs hinder the growth of the market.

Biologics are among the most promising avenues in the pharmaceutical industry, offering a unique approach to treating various diseases and medical conditions. The biologics market is constantly growing because pharma and biotechnology companies enormously invest in improving their production facilities. The increasing number of cases and diagnoses of chronic diseases requires the availability of sophisticated diagnostic and treatment drugs, which has boosted the global biologics market. Furthermore, rising demand, higher acceptance of innovative therapies, and increasing clinical trials are expected to drive market growth. However, approving biosimilars is one of the main aspects limiting the biologics market expansion.

North America accounted for a major share of the global biologics market in 2023. The North America biologics market is segmented into the US, Canada, and Mexico. The key factors driving the market growth in this region is the high prevalence of chronic diseases, numerous leading biopharmaceutical companies, favorable reimbursement policies, and significant investments in research and development. According to an article published in JAMA Network, biologics accounted for 37% of total drug spending in the US. The increasing share of prescriptions for biologics and growing investments in developing targeted drugs are contributing to the market growth. Additionally, approvals for several novel biological drugs such as antisense, gene therapy, and RNAi therapeutics are expected to drive market growth further.

Evolution of Biotechnology Industry in Developing Regions to Provide Market Opportunities in Future

In modern biotechnology, antibodies are required in numerous processes, from basic research to innovative medical evaluations. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in antibody-based diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of the biotechnology industry in regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most advantageous destinations for the biotechnology industry. Continuous advancements in the fields of biotechnology, genetics, and cell biology have contributed to identifying the potential of therapeutics for targeted therapies. As the biotechnology industry expands scientists' toolboxes, the combination of basic research, translational studies, and clinical trials will continue to develop, investigate, and test additional compounds, techniques, and therapeutic pathways. Biotechnology is a strategic sector for China. The Made in China 2025 initiative aims to produce high-tech products, including innovative medicines. The plan introduced targets for Chinese pharmaceutical companies to spur biotechnology innovation and increase exports. Furthermore, these Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing evolution of the biotechnology industry in developing regions is expected to create opportunities for the biologics market in the coming years.

Product -Based Insights

Based on product, the biologics market is divided into monoclonal antibodies, vaccines, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023 and is likely to register the highest CAGR during 2023-2031.

Application -Based Insights

The market, based on application, is divided into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest share of the market in 2023 and is anticipated to register the highest CAGR during 2023-2031.

Source -Based Insights

Based on source, the market is segmented into mammalian and microbial. The microbial segment held a larger market share in 2023. The mammalian is estimated to record a faster CAGR during 2023-2031. Mammalian expression systems are mainly used to develop recombinant proteins and vaccines based on viral vectors. The most frequently used mammalian cell lines are CHO and HEK. Products such as Perjeta (pertuzumab), Adcetris (brentuximab vedotin), Kadycla (trastuzumab emtansine), Shingrix (zoster vaccine), and Aimovig (erenumab) are among the products manufactured in mammalian expression systems.

Biologics Market: Competitive Landscape and Key Developments

AbbVie Inc.; Pfizer Inc.; Samsung Biologics; ADMA Biologics, Inc.; WuXi Biologics; Catalent, Inc; AGC Biologics; Crescendo Biologics Limited; Zumutor Biologics INC; Theriva Biologics; AstraZeneca; Amgen Inc.; Avecia Biologics; and Quality Assistance s.a. are among the key companies operating in the biologics market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the biologics market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Biologics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Biologics Market - Key Market Dynamics

  • 5.1 Biologics Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Increasing Prevalence of Chronic Diseases
    • 5.2.2 Preference for Outsourcing Manufacturing Operations
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Biologics
  • 5.4 Market Opportunities
    • 5.4.1 Evolution of Biotechnology in Developing Regions
  • 5.5 Future Trends
    • 5.5.1 Strategic Initiatives by Companies
  • 5.6 Impact of Drivers and Restraints:

6. Biologics Market - Global Market Analysis

  • 6.1 Biologics Market Revenue (US$ Million), 2021-2031
  • 6.2 Biologics Market Forecast Analysis

7. Biologics Market Analysis - by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Overview
    • 7.1.2 Monoclonal Antibodies: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Vaccine
    • 7.2.1 Overview
    • 7.2.2 Vaccine: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Recombinant Hormones/Proteins
    • 7.3.1 Overview
    • 7.3.2 Recombinant Hormones/Proteins: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Cell and Gene Therapy
    • 7.4.1 Overview
    • 7.4.2 Cell and Gene Therapy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

8. Biologics Market Analysis - by Application

  • 8.1 Cancer
    • 8.1.1 Overview
    • 8.1.2 Cancer: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Infectious Diseases
    • 8.2.1 Overview
    • 8.2.2 Infectious Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Autoimmune Diseases
    • 8.3.1 Overview
    • 8.3.2 Autoimmune Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

9. Biologics Market Analysis - by Source

  • 9.1 Mammalian
    • 9.1.1 Overview
    • 9.1.2 Mammalian: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Microbial
    • 9.2.1 Overview
    • 9.2.2 Microbial: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

10. Biologics Market Analysis - by Manufacturing

  • 10.1 Outsourced
    • 10.1.1 Overview
    • 10.1.2 Outsourced: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 In-house
    • 10.2.1 Overview
    • 10.2.2 In-house: Biologics Market - Revenue and Forecast to 2031 (US$ Million)

11. Biologics Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Biologics Market Overview
    • 11.2.2 North America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Biologics Market Breakdown, by Product
      • 11.2.3.1 North America: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.2.4 North America: Biologics Market Breakdown, by Application
      • 11.2.4.1 North America: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.2.5 North America: Biologics Market Breakdown, by Source
      • 11.2.5.1 North America: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.2.6 North America: Biologics Market Breakdown, by Manufacturing
      • 11.2.6.1 North America: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.2.7 North America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 North America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.2 United States: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 United States: Biologics Market Breakdown, by Product
        • 11.2.7.2.2 United States: Biologics Market Breakdown, by Application
        • 11.2.7.2.3 United States: Biologics Market Breakdown, by Source
        • 11.2.7.2.4 United States: Biologics Market Breakdown, by Manufacturing
      • 11.2.7.3 Canada: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Canada: Biologics Market Breakdown, by Product
        • 11.2.7.3.2 Canada: Biologics Market Breakdown, by Application
        • 11.2.7.3.3 Canada: Biologics Market Breakdown, by Source
        • 11.2.7.3.4 Canada: Biologics Market Breakdown, by Manufacturing
      • 11.2.7.4 Mexico: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.4.1 Mexico: Biologics Market Breakdown, by Product
        • 11.2.7.4.2 Mexico: Biologics Market Breakdown, by Application
        • 11.2.7.4.3 Mexico: Biologics Market Breakdown, by Source
        • 11.2.7.4.4 Mexico: Biologics Market Breakdown, by Manufacturing
  • 11.3 Europe
    • 11.3.1 Europe Biologics Market Overview
    • 11.3.2 Europe: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Biologics Market Breakdown, by Product
      • 11.3.3.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.3.4 Europe: Biologics Market Breakdown, by Application
      • 11.3.4.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.3.5 Europe: Biologics Market Breakdown, by Source
      • 11.3.5.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.3.6 Europe: Biologics Market Breakdown, by Manufacturing
      • 11.3.6.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.3.7 Europe: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Europe: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.2 Germany: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 Germany: Biologics Market Breakdown, by Product
        • 11.3.7.2.2 Germany: Biologics Market Breakdown, by Application
        • 11.3.7.2.3 Germany: Biologics Market Breakdown, by Source
        • 11.3.7.2.4 Germany: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.3 United Kingdom: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 United Kingdom: Biologics Market Breakdown, by Product
        • 11.3.7.3.2 United Kingdom: Biologics Market Breakdown, by Application
        • 11.3.7.3.3 United Kingdom: Biologics Market Breakdown, by Source
        • 11.3.7.3.4 United Kingdom: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.4 Italy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 Italy: Biologics Market Breakdown, by Product
        • 11.3.7.4.2 Italy: Biologics Market Breakdown, by Application
        • 11.3.7.4.3 Italy: Biologics Market Breakdown, by Source
        • 11.3.7.4.4 Italy: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.5 France: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 France: Biologics Market Breakdown, by Product
        • 11.3.7.5.2 France: Biologics Market Breakdown, by Application
        • 11.3.7.5.3 France: Biologics Market Breakdown, by Source
        • 11.3.7.5.4 France: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.6 Spain: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Spain: Biologics Market Breakdown, by Product
        • 11.3.7.6.2 Spain: Biologics Market Breakdown, by Application
        • 11.3.7.6.3 Spain: Biologics Market Breakdown, by Source
        • 11.3.7.6.4 Spain: Biologics Market Breakdown, by Manufacturing
      • 11.3.7.7 Rest of Europe: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.7.1 Rest of Europe: Biologics Market Breakdown, by Product
        • 11.3.7.7.2 Rest of Europe: Biologics Market Breakdown, by Application
        • 11.3.7.7.3 Rest of Europe: Biologics Market Breakdown, by Source
        • 11.3.7.7.4 Rest of Europe: Biologics Market Breakdown, by Manufacturing
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Biologics Market Overview
    • 11.4.2 Asia Pacific: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.3 Asia Pacific: Biologics Market Breakdown, by Product
      • 11.4.3.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.4.4 Asia Pacific: Biologics Market Breakdown, by Application
      • 11.4.4.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.4.5 Asia Pacific: Biologics Market Breakdown, by Source
      • 11.4.5.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.4.6 Asia Pacific: Biologics Market Breakdown, by Manufacturing
      • 11.4.6.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.4.7 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.1 Asia Pacific: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.4.7.2 China: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.2.1 China: Biologics Market Breakdown, by Product
        • 11.4.7.2.2 China: Biologics Market Breakdown, by Application
        • 11.4.7.2.3 China: Biologics Market Breakdown, by Source
        • 11.4.7.2.4 China: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.3 India: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.3.1 India: Biologics Market Breakdown, by Product
        • 11.4.7.3.2 India: Biologics Market Breakdown, by Application
        • 11.4.7.3.3 India: Biologics Market Breakdown, by Source
        • 11.4.7.3.4 India: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.4 Japan: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.4.1 Japan: Biologics Market Breakdown, by Product
        • 11.4.7.4.2 Japan: Biologics Market Breakdown, by Application
        • 11.4.7.4.3 Japan: Biologics Market Breakdown, by Source
        • 11.4.7.4.4 Japan: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.5 South Korea: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.5.1 South Korea: Biologics Market Breakdown, by Product
        • 11.4.7.5.2 South Korea: Biologics Market Breakdown, by Application
        • 11.4.7.5.3 South Korea: Biologics Market Breakdown, by Source
        • 11.4.7.5.4 South Korea: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.6 Australia: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.6.1 Australia: Biologics Market Breakdown, by Product
        • 11.4.7.6.2 Australia: Biologics Market Breakdown, by Application
        • 11.4.7.6.3 Australia: Biologics Market Breakdown, by Source
        • 11.4.7.6.4 Australia: Biologics Market Breakdown, by Manufacturing
      • 11.4.7.7 Rest of APAC: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.7.7.1 Rest of APAC: Biologics Market Breakdown, by Product
        • 11.4.7.7.2 Rest of APAC: Biologics Market Breakdown, by Application
        • 11.4.7.7.3 Rest of APAC: Biologics Market Breakdown, by Source
        • 11.4.7.7.4 Rest of APAC: Biologics Market Breakdown, by Manufacturing
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Biologics Market Overview
    • 11.5.2 Middle East and Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.3 Middle East and Africa: Biologics Market Breakdown, by Product
      • 11.5.3.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.5.4 Middle East and Africa: Biologics Market Breakdown, by Application
      • 11.5.4.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.5.5 Middle East and Africa: Biologics Market Breakdown, by Source
      • 11.5.5.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.5.6 Middle East and Africa: Biologics Market Breakdown, by Manufacturing
      • 11.5.6.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.5.7 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.1 Middle East and Africa: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.5.7.2 South Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.2.1 South Africa: Biologics Market Breakdown, by Product
        • 11.5.7.2.2 South Africa: Biologics Market Breakdown, by Application
        • 11.5.7.2.3 South Africa: Biologics Market Breakdown, by Source
        • 11.5.7.2.4 South Africa: Biologics Market Breakdown, by Manufacturing
      • 11.5.7.3 Saudi Arabia: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.3.1 Saudi Arabia: Biologics Market Breakdown, by Product
        • 11.5.7.3.2 Saudi Arabia: Biologics Market Breakdown, by Application
        • 11.5.7.3.3 Saudi Arabia: Biologics Market Breakdown, by Source
        • 11.5.7.3.4 Saudi Arabia: Biologics Market Breakdown, by Manufacturing
      • 11.5.7.4 United Arab Emirates: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.4.1 United Arab Emirates: Biologics Market Breakdown, by Product
        • 11.5.7.4.2 United Arab Emirates: Biologics Market Breakdown, by Application
        • 11.5.7.4.3 United Arab Emirates: Biologics Market Breakdown, by Source
        • 11.5.7.4.4 United Arab Emirates: Biologics Market Breakdown, by Manufacturing
      • 11.5.7.5 Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.7.5.1 Rest of Middle East and Africa: Biologics Market Breakdown, by Product
        • 11.5.7.5.2 Rest of Middle East and Africa: Biologics Market Breakdown, by Application
        • 11.5.7.5.3 Rest of Middle East and Africa: Biologics Market Breakdown, by Source
        • 11.5.7.5.4 Rest of Middle East and Africa: Biologics Market Breakdown, by Manufacturing
  • 11.6 South and Central America
    • 11.6.1 South and Central America Biologics Market Overview
    • 11.6.2 South and Central America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.6.3 South and Central America: Biologics Market Breakdown, by Product
      • 11.6.3.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Product
    • 11.6.4 South and Central America: Biologics Market Breakdown, by Application
      • 11.6.4.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Application
    • 11.6.5 South and Central America: Biologics Market Breakdown, by Source
      • 11.6.5.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Source
    • 11.6.6 South and Central America: Biologics Market Breakdown, by Manufacturing
      • 11.6.6.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Manufacturing
    • 11.6.7 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.1 South and Central America: Biologics Market - Revenue and Forecast Analysis - by Country
      • 11.6.7.2 Brazil: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.2.1 Brazil: Biologics Market Breakdown, by Product
        • 11.6.7.2.2 Brazil: Biologics Market Breakdown, by Application
        • 11.6.7.2.3 Brazil: Biologics Market Breakdown, by Source
        • 11.6.7.2.4 Brazil: Biologics Market Breakdown, by Manufacturing
      • 11.6.7.3 Argentina: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.3.1 Argentina: Biologics Market Breakdown, by Product
        • 11.6.7.3.2 Argentina: Biologics Market Breakdown, by Application
        • 11.6.7.3.3 Argentina: Biologics Market Breakdown, by Source
        • 11.6.7.3.4 Argentina: Biologics Market Breakdown, by Manufacturing
      • 11.6.7.4 Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.7.4.1 Rest of South and Central America: Biologics Market Breakdown, by Product
        • 11.6.7.4.2 Rest of South and Central America: Biologics Market Breakdown, by Application
        • 11.6.7.4.3 Rest of South and Central America: Biologics Market Breakdown, by Source
        • 11.6.7.4.4 Rest of South and Central America: Biologics Market Breakdown, by Manufacturing

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Biologics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 AbbVie Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Pfizer Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Samsung Biologics Co Ltd
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 ADMA Biologics, Inc.
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 WuXi Biologics Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Catalent Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AGC Biologics AS
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 AstraZeneca Plc
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Amgen Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Nitto Avecia
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Quality Assistance s.a.
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners

List Of Tables

  • Table 1. Biologics Market Segmentation
  • Table 2. Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Product
  • Table 4. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 5. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Source
  • Table 6. Biologics Market - Revenue and Forecast to 2031 (US$ Million) - by Manufacturing
  • Table 7. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 8. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 9. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 10. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 11. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 12. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 13. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 14. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 15. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 16. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 17. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 18. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 19. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 20. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 21. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 22. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 23. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 24. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 25. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 26. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 27. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 28. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 29. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 30. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 31. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 32. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 33. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 34. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 35. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 36. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 37. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 38. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 39. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 40. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 41. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 42. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 43. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 44. France: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 45. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 46. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 47. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 48. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 49. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 50. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 51. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 52. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 53. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 54. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 55. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 56. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 57. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 58. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 59. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 60. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 61. China: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 62. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 63. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 64. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 65. India: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 66. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 67. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 68. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 69. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 70. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 71. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 72. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 73. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 74. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 75. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 76. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 77. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 78. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 79. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 80. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 81. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 82. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 83. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 84. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 85. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 86. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 87. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 88. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 89. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 90. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 91. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 92. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 93. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 94. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 95. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 96. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 97. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 98. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 99. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 100. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 101. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 102. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 103. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 104. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 105. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 106. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 107. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 108. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 109. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 110. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 111. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 112. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 113. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 114. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 115. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 116. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Product
  • Table 117. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 118. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Source
  • Table 119. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million) - by Manufacturing
  • Table 120. Recent Organic Growth Strategies in Biologics Market
  • Table 121. Recent Inorganic Growth Strategies in the Biologics Market

List Of Figures

  • Figure 1. Biologics Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Vaccine: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Infectious Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Others: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Microbial: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. In-house: Biologics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Biologics Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 23. North America: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. North America: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 25. North America: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 26. North America: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 27. North America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 28. North America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 29. United States: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Canada: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Mexico: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Europe: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 34. Europe: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 35. Europe: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 36. Europe: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 37. Europe: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 38. Germany: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. United Kingdom: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Italy: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. France: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Spain: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Rest of Europe: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. Asia Pacific: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Asia Pacific: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 46. Asia Pacific: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 47. Asia Pacific: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 48. Asia Pacific: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 49. Asia Pacific: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 50. China: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. India: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Japan: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. South Korea: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Australia: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Rest of APAC: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Middle East and Africa: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 58. Middle East and Africa: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 59. Middle East and Africa: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 60. Middle East and Africa: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 61. Middle East and Africa: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 62. South Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Saudi Arabia: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 64. United Arab Emirates: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Rest of Middle East and Africa: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. South and Central America: Biologics Market Breakdown, by Product (2023 and 2031)
  • Figure 68. South and Central America: Biologics Market Breakdown, by Application (2023 and 2031)
  • Figure 69. South and Central America: Biologics Market Breakdown, by Source (2023 and 2031)
  • Figure 70. South and Central America: Biologics Market Breakdown, by Manufacturing (2023 and 2031)
  • Figure 71. South and Central America: Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 72. Brazil: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 73. Argentina: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 74. Rest of South and Central America: Biologics Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 75. Growth Strategies in Biologics Market